Structural optimization and structure-activity relationships of N 2-(4-(4-methylpiperazin-1-yl)phenyl)- N 8-phenyl-9 H -purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations

Journal of Medicinal Chemistry

Volumn 55, Issue 23, 2012, Pages 10685-10699

  Yang, Jiao ^a,b   Wang, Li Jiao ^a   Liu, Jing Jing ^a   Zhong, Lei ^a   Zheng, Ren Lin ^a   Xu, Yong ^a   Ji, Pan ^a   Zhang, Chun Hui ^a   Wang, Wen Jing ^a   Lin, Xing Dong ^a   Li, Lin Li ^b   Wei, Yu Quan ^a   Yang, Sheng Yong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [9 CYCLOPENTYL 8 (PHENYLAMINO) 9H PURIN 2 YLAMINO]PHENYLAMINO]ETHANOL; 3 [9 CYCLOPENTYL 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYLAMINO] 9H PURIN 8 YLAMINO]PHENOL; 9 (3,5 DIMETHYLPHENYL) N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] N 8 PHENYL 9H PURINE 2,8 DIAMINE; 9 CYCLOHEXYL N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] N 8 PHENYL 9H PURINE 2,8 DIAMINE; 9 CYCLOPENTYL N 2 (4 MORPHOLINOPHENYL) N 8 PHENYL 9H PURINE 2,8 DIAMINE; 9 CYCLOPENTYL N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] N 8 (3 NITROPHENYL) 9H PURINE 2,8 DIAMINE; 9 CYCLOPENTYL N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] N 8 3 TOLYL 9H PURINE 2,8 DIAMINE; 9 CYCLOPENTYL N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] N 8 PHENYL 9H PURINE 2,8 DIAMINE; 9 CYCLOPENTYL N 2 [4 (4 METHYLPIPERIDIN 1 YL)PHENYL] N 8 PHENYL 9H PURINE 2,8 DIAMINE; 9 CYCLOPENTYL N 2,N 8 DIPHENYL 9H PURINE 2,8 DIAMINE; 9 CYCLOPENTYL N 8 (2,5 DICHLOROPHENYL) N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] 9H PURINE 2,8 DIAMINE; 9 CYCLOPENTYL N 8 (3 ETHYNYLPHENYL) N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] 9H PURINE 2,8 DIAMINE; 9 CYCLOPROPYL N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] N 8 PHENYL 9H PURINE 2,8 DIAMINE; 9 ISOPROPYL N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] N 8 PHENYL 9H PURINE 2,8 DIAMINE; 9 METHYL N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] N 8 PHENYL 9H PURINE 2,8 DIAMINE; AFATINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; N (4 CHLOROPHENYL) 3 [9 CYCLOPENTYL 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYLAMINO] 9H PURIN 8 YLAMINO]BENZAMIDE; N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] N 8 PHENYL 9H PURINE 2,8 DIAMINE DERIVATIVE; N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] N 8,9 DIPHENYL 9H PURINE 2,8 DIAMINE; N 8 (3 CHLOROPHENYL) 9 CYCLOPENTYL N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] 9H PURINE 2,8 DIAMINE; N 8 (4 BROMO 2 FLUOROPHENYL) 9 CYCLOPENTYL N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] 9H PURINE 2,8 DIAMINE; N 8 (4 BROMOPHENYL) 9 CYCLOPENTYL N 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYL] 9H PURINE 2,8 DIAMINE; N [3 [9 CYCLOPENTYL 2 [4 (4 METHYLPIPERAZIN 1 YL)PHENYLAMINO] 9H PURIN 8 YLAMINO]PHENYL]BENZAMIDE; N [4 [9 CYCLOPENTYL 8 (PHENYLAMINO) 9H PURIN 2 YLAMINO]PHENYL]ACETAMIDE; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GENE MUTATION; IC 50; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DOCKING; MOUSE; NONHUMAN; RAT; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR REGRESSION; TUMOR VOLUME;

CELL LINE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PURINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84870998201     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301365e     Document Type: Article

References (32)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics CA Cancer J. Clin. 2012, 62, 10-29
2. Sequist, L. V.; Martins, R. G.; Spigel, D.; Grunberg, S. M.; Spira, A.; Jänne, P. A.; Joshi, V. A.; McCollum, D.; Evans, T. L.; Muzikansky, A.; Kuhlmann, G. L.; Han, M.; Goldberg, J. S.; Settleman, J.; Iafrate, A. J.; Engelman, J. A.; Haber, D. A.; Johnson, B. E.; Lynch, T. J. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations J. Clin. Oncol. 2008, 26, 2442-2449
3. Sharma, S. V.; Bell, D. W.; Settleman, J.; Haber, D. A. Epidermal growth factor receptor mutations in lung cancer Nat. Rev. Cancer. 2007, 7, 169-181
4. Johnson, J. R.; Cohen, M.; Sridhara, R.; Chen, Y. F.; Williams, G. M.; Duan, J.; Gobburu, J.; Booth, B.; Benson, K.; Leighton, J.; Hsieh, L. S.; Chidambaram, N.; Zimmerman, P.; Pazdur, R. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen Clin. Cancer Res. 2005, 11, 6414-6421
5. Han, S. W.; Kim, T. Y.; Hwang, P. G.; Jeong, S.; Kim, J.; Choi, I. S.; Oh, D. Y.; Kim, J. H.; Kim, D. W.; Chung, D. H.; Im, S. A.; Kim, Y. T.; Lee, J. S.; Heo, D. S.; Bang, Y. J.; Kim, N. K. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib J. Clin. Oncol. 2005, 23, 2493-2501
6. Greulich, H.; Chen, T. H.; Feng, W.; Jänne, P. A.; Alvarez, J. V.; Zappaterra, M.; Bulmer, S. E.; Frank, D. A.; Hahn, W. C.; Sellers, W. R.; Meyerson, M. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants PLoS Med. 2005, 2, e313
7. Ciaardiello, F.; Tortora, G. EGFR antagonists in cancer treatment N. Engl. J. Med. 2008, 358, 1160-1174
8. Sordella, R.; Bell, D. W.; Haber, D. A.; Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways Science 2004, 305, 1163-1167
9. Mok, T. S.; Wu, Y. L.; Thongprasert, S.; Yang, C. H.; Chu, D. T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; Nishiwaki, Y.; Ohe, Y.; Yang, J. J.; Chewaskulyong, B.; Jiang, H.; Duffield, E. L.; Watkins, C. L.; Armour, A. A.; Fukuoka, M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N. Engl. J. Med. 2009, 361, 947-957
10. Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Jänne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 2005, 352, 786-792
11. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2005, 2, e73
12. Kwak, E. L.; Sordella, R.; Bell, D. W.; Godin-Heymann, N.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Driscoll, D. R.; Fidias, P.; Lynch, T. J.; Rabindran, S. K.; McGinnis, J. P.; Wissner, A.; Sharma, S. V.; Isselbacher, K. J.; Settleman, J.; Haber, D. A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 7665-7670
13. Yun, C. H.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.; Greulich, H.; Wong, K. K.; Meyerson, M.; Eck, M. J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 2070-2075
14. Eck, M. J.; Yun, C. H. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer Biochim. Biophys. Acta 2010, 1804, 559-566
15. Mishani, E.; Abourbeh, G.; Jacobson, O.; Dissoki, S.; Ben Daniel, R.; Rozen, Y.; Shaul, M.; Levitzki, A. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors J. Med. Chem. 2005, 48, 5337-5348
16. 790 mutant J. Med. Chem. 2012, 55, 2711-2723
17. Zhou, W. J.; Ercan, D.; Chen, L.; Yun, C. H.; Li, D.; Capelletti, M.; Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong, K. K.; Eck, M. J.; Gray, N. S.; Jänne, P. A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 2009, 462, 1070-1074
18. Kwak, E. L.; Sordella, R.; Bell, D. W.; Godin, H. N.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Driscoll, D. R.; Fidias, P.; Lynch., T. J.; Rabindran, S. K.; McGinnis, J. P.; Wissner, A.; Sharma, S. V.; Isselbacher, K. J.; Settleman, J.; Haber, D. A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 7665-7670
19. Belani, C. P. The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors Cancer Invest. 2010, 28, 413-423
20. Wong, K. K. HKI-272 in non small cell lung cancer Clin. Cancer Res. 2007, 13, 4593-4596
21. Erlichman, C.; Hidalgo, M.; Boni, J. P.; Martins, P.; Quinn, S. E.; Zacharchuk, C.; Amorusi, P.; Adjei, A. A.; Rowinsky, E. K. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors J. Clin. Oncol. 2006, 24, 2252-2260
22. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K. K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 2008, 27, 4702-4711
23. Engelman, J. A.; Zejnullahu, F.; Gale, C. M.; Lifshits, E.; Gonzales, A. J.; Shimamura, T.; Zhao, F.; Vincent, P. W.; Naumov, G. N.; Bradner, J. E.; Althaus, I. W.; Gandhi, L.; Shapiro, G. I.; Nelson, J. M.; Heymach, J. V.; Meyerson, M.; Wong, K. K.; Jänne, P. A. PF00299804, an irreversible Pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib Cancer Res. 2007, 67, 11924-11932
24. Sos, M. L.; Rode, H. B.; Heynck, S.; Peifer, M.; Fischer, F.; Klüter, S.; Pawar, V. G.; Reuter, C.; Heuckmann, J. M.; Weiss, J.; Ruddigkeit, L.; Rabiller, M.; Koker, M.; Simard, J. R.; Getlik, M.; Yuza, Y.; Chen, T. H.; Greulich, H.; Thomas, R. K.; Rauh, D. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation Cancer Res. 2010, 70, 868-874
25. Kim, Y.; Ko, J.; Cui, Z.; Abolhoda, A.; Ahn, J. S.; Ou, S. H.; Ahn, M. J.; Park, K. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor Mol. Cancer Ther. 2012, 11, 784-791
26. Ercan, D.; Zejnullahu, K.; Yonesaka, K.; Xiao, Y.; Capelletti, M.; Rogers, A.; Lifshits, E.; Brown, A.; Lee, C.; Christensen, J. G.; Kwiatkowski, D. J.; Engelman, J. A.; Jänne, P. A. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor Oncogene 2010, 29, 2346-2356
27. Pan, Y.; Xu, Y.; Feng, S.; Luo, S.; Zheng, R.; Yang, J.; Wang, L.; Zhong, L.; Yang, H. Y.; Wang, B. L.; Yu, Y.; Liu, J.; Cao, Z.; Wang, X.; Ji, P.; Wang, Z.; Chen, X.; Zhang, S.; Wei, Y. Q.; Yang, S. Y. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo Mol. Cancer Ther. 2012, 11, 952-962
28. Antonello, A.; Tarozzi, A.; Morroni, F.; Cavalli, A.; Rosini, M.; Hrelia, P.; Bolognesi, M. L.; Melchiorre, C. Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects J. Med. Chem. 2006, 49, 6642-6645
29. Wu, C. H.; Coumar, M. S.; Chu, C. Y.; Lin, W. H.; Chen, Y. R.; Chen, C. T.; Shiao, H. Y.; Rafi, S.; Wang, S. Y.; Hsu, H.; Chen, C. H.; Chang, C. Y.; Chang, T. Y.; Lien, T. W.; Fang, M. Y.; Yeh, K. C.; Chen, C. P.; Yeh, T. K.; Hsieh, S. H.; Hsu, J. T.; Liao, C. C.; Chao, Y. S.; Hsieh, H. P. Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency J. Med. Chem. 2010, 53, 7316-7326
30. Ishikawa, T.; Seto, M.; Banno, H.; Kawakita, Y.; Oorui, M.; Taniguchi, T.; Ohta, Y.; Tamura, T.; Nakayama, A.; Miki, H.; Kamiguchi, H.; Tanaka, T.; Habuka, N.; Sogabe, S.; Yano, J.; Aertgeerts, K.; Kamiyama, K. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold J. Med. Chem. 2011, 54, 8030-8050
31. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748
32. Yun, C. H.; Boggon, T. J.; Li, Y.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 2007, 11, 217-227